Menu
Search
|

Menu

Close
X

Jazz Pharmaceuticals PLC JAZZ.OQ (NASDAQ Stock Exchange Global Select Market)

135.55 USD
+1.10 (+0.82%)
As of 4:00 PM EDT
chart
Previous Close 134.45
Open 135.19
Volume 290,005
3m Avg Volume 245,934
Today’s High 136.03
Today’s Low 133.46
52 Week High 183.96
52 Week Low 115.36
Shares Outstanding (mil) 57.06
Market Capitalization (mil) 7,671.14
Forward P/E 18.40
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.94 Mean rating from 18 analysts

KEY STATS

Revenue (mm, USD)
FY18
1,891
FY17
1,619
FY16
1,488
EPS (USD)
FY18
7.308
FY17
5.426
FY16
6.530
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
18.40
41.05
Price to Sales (TTM)
vs sector
4.06
8.91
Price to Book (MRQ)
vs sector
2.80
4.65
Price to Cash Flow (TTM)
vs sector
11.56
28.95
Total Debt to Equity (MRQ)
vs sector
57.90
17.48
LT Debt to Equity (MRQ)
vs sector
56.68
13.83
Return on Investment (TTM)
vs sector
9.23
12.19
Return on Equity (TTM)
vs sector
16.35
13.29

EXECUTIVE LEADERSHIP

Bruce Cozadd
Chairman of the Board, Chief Executive Officer, Since 2009
Salary: $950,385.00
Bonus: --
Daniel Swisher
President, Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Matthew Young
Chief Financial Officer, Executive Vice President, Since 2015
Salary: $545,385.00
Bonus: --
Michael Miller
Executive Vice President - U.S. Commercial, Since 2017
Salary: $266,154.00
Bonus: $30,000.00
Karen Wilson
Senior Vice President - Finance, Principal Accounting Officer, Since 2013
Salary: $235,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Fifth Fl
Waterloo Exchange, Waterloo Road
DUBLIN     4

Phone: +3531.6347800

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

SPONSORED STORIES